Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absorb, adjudicated, adrenocortical, African, Aftab, Air, alphalex, alphalexTM, Antonio, assortment, BioInvent, biparatopic, bolster, bond, capping, catch, cetuximab, Cipla, circulation, classical, CMS, complementary, constantly, correspondingly, Cybrexa, Dana, dealing, deconsolidation, descent, detriment, discontinued, DOJ, East, emotionally, engineering, estate, exatecan, excise, exempt, exhaustive, extinguished, favezelimab, forefront, formation, honor, III, inflation, inquiry, irreversible, killer, Kingdom, largest, macroeconomic, macrophage, mediate, mentioned, municipal, narrowed, narrowing, noncancellable, Occupational, Oncoloy, overtime, PDC, peer, Philadelphia, plenary, poster, pretreated, RAS, ratably, relatlimab, row, RSU, Russian, Ryvu, Sairopa, SCCHN, SIRP, STING, streamline, Taiho, topoisomerase, undermine, underway, unduly, unfriendly, vacated, VIE, War, withdrew, zanzalintinib
Removed:
accelerate, acetate, adenocarcinoma, adjacent, administered, agile, antagonist, anticancer, automatic, biology, bone, BRAF, broaden, CABINET, Calithera, CAMILLA, carcinoid, cardiovascular, CheckMate, chemotherapeutic, China, clarifying, Codification, collaborator, commercializing, comparator, CR, demanding, depositing, device, diabetic, dichloride, durvalumab, educational, endometrial, escalating, EXAMINER, execution, exercisable, exploratory, externally, FASB, field, focusing, foot, gastric, gastroesophageal, highlighted, hormone, imposition, induction, inflammation, instituted, intent, Interaction, IRRC, junction, largely, leiomyosarcoma, lender, lieu, Ligand, line, malignant, mesothelioma, metabolic, Mirati, monthly, movement, NaN, nephropathy, neuroendocrine, nuclear, Onyx, optional, papillary, PAPMET, partnered, Pat, PD, PDIGREE, pemetrexed, pharmacology, possession, prevailing, pursued, radiation, radical, radioiodine, ramucirumab, randomize, reacquire, recurrent, removing, resumed, reversible, robust, secured, signal, sitravatinib, sixty, skeletal, social, soft, Southwest, summarize, switched, Switzerland, telaglenastat, temozolomide, thirty, tolerate, top, vemurafenib, zelboraf
Filing tables
Filing exhibits
Related press release
Associated EXEL transcripts
EXEL similar filings
Filing view
External links
Exhibit 10.20
TERMS OF EMPLOYMENT – DANA T. AFTAB
(as of December 15, 2022)
TITLE: Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer
ANNUAL BASE SALARY: $560,000.22 annually
BONUS TARGET: 50% of Annual Base salary
INITIAL RESTRICTED STOCK UNIT (RSU) AWARD: 100,000 shares of Exelixis, Inc. common stock pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The vesting schedule for this RSU award is 1/4th on the first established RSU vesting date following the one year anniversary of the grant date (the “Initial RSU Vesting Date”) and 1/4th of the original number of shares subject to the RSU award on each succeeding annual anniversary of the Initial RSU Vesting Date until fully-vested, provided that vesting ceases upon termination of “continuous service” with Exelixis, Inc., as such term is defined in the Exelixis, Inc. 2017 Equity Incentive Plan.